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To determine and validate of captopril in presence of apigenin by liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) in rat plasma. The captopril and apigenin were extracted from rat plasma by protein
precipitation with acetonitrile. Sample containing captopril and apigenin were analyzed by using LC-MS/MS with
C18 column Acquity® (100 mm×21 mm), 1.7 m particles size column at 40 C. The gradient system of mobile
phase composition was a mixture of 0.1% formic acid and acetonitrile (60; 40 v/v), with flow rate 0.3 ml/second.
Mass detection was performed on Waters Xevo Triple Quadrupole equipped with an electrospray ionization
(ESI) source in positive ion mode in the multiple reaction monitoring (MRM) modes. Captopril was detected
at m/z 415> 21616, apigenin was detected at m/z 27113> 15307 and propranolol an internal standard was
detected at m/z 260> 18317. Results: The method was validated according to EMEA guidelines which showed
good reproducibility and linearity of 0.9992, the LLOQ were 10 ng/ml for captopril. The precision (%CV) value of
Within-run and between-run analysis is 3.90–10.90% and 3.77–8.13% whereas the accuracy (%diff) of captopril
was less than 20%. Stability studies revealed that captopril has been stable for 6 hours at room temperature,
three freeze-thaw cycles, and at least 120 days at −40 C. Conclusion: The developed LC-MS/MS method
is valid to evaluate captopril in present of apigenin in vitro and meet the requirement of linearity, accuracy,
selectivity, precision, matrix effect, and stability according to EMEA 2011.
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1. INTRODUCTION
Captopril is the first drug from the class of Angiotensin Con-
verting Enzyme inhibitors (ACEI) which works by preventing
the changes of angiotensin I to angiotensin II (potential vaso-
constrictor and aldosterone secretion stimulus). ACE inhibitors
prevent the degradation of bradykinin and stimulate the synthe-
sis of compounds other vasodilators include prostaglandin E2
and prostacyclin, causing vasodilation and decreased secretion of
aldosterone causes sodium and water excretion, and potassium
retention. As a result, a decline in blood pressure in patients
with hypertension.1 Apigenin was one of the bioactive marker
compounds from Apium graveolens (celery), that is used in tra-
ditional medicine for a diuretic, antihypertensive.23 Herbs are
sold as food supplements, because of that, the companies are
not required to prove the efficacy of the herbs or determine
the side effects or interaction of the products.4 Although most
people believe that herbs are harmless plants, there are some
drugs were developed from plants, such as digitalis, morphine,
atropine, and several chemotherapeutic agents. Herbs can effect
body functions; therefore, when herbs are taken together with
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drugs, interaction are possible. Herbal medicine has increased
in popularity, but they do not inform their medical practition-
ers of such use.5 Herbs preparation in combination with a syn-
thetic drug taken simultaneously may interact with the synergistic
effect result or can increase the side effect.6 Because of that,
it is necessary to study the interaction between drug and herb.
To support clinical investigations, especially in pharmacokinetics
interaction, a reliable analytical method with adequate sensitiv-
ity is necessary. Several HPLC, LC-UV and LC-MS/MS method
have been conducted previously for the determination of capto-
pril in biological sample.7 However, to the authors’ knowledge,
the combination of captopril and apigenin has not been reported.
The present study describes a simple, rapid, precise, and accu-
rate LC-MS/MS method for determining captopril in present of
apigenin in rat plasma.
2. EXPERIMENTAL DETAILS
2.1. Material and Methods
Captopril and propranolol were obtained from Zhejiang Huahai
Pharmaceutical and apigenin from Shaanxi Jintai Biolog-
ical Engineering. Acetonitrile, 2,4-dibromoacetophenon, and
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methanol were HPLC grade and were purchased from Merck.
The reagents that used were of analytical or reagent grade purity.
Ultrapure water was generated by Millipore Direct-Q® ultra-pure
water system. Sprague-Dawley rat plasma was supplied by Bogor
Agriculture Institute and used as a blank matrix in the preparation
of calibration standards and QC samples.
2.2. Standard Solutions, Calibration Standards, and
QC Samples Preparation
Primary stock solutions of captopril, respectively, with the con-
centration of 100 g/ml was prepared by dissolving 40 mg in
100 ml water. Primary stock solutions of propranolol (1 mg/ml)
and apigenin (1 mg/ml) were prepared by dissolving 40 mg in
100 ml methanol. Calibration standards and QC samples were
prepared by diluting the stock solution with Sprague-Dawley
rat plasma to form the calibration standards of captopril in the
present of apigenin (10, 25, 50, 100, 250, and 500 ng/ml) and
QC samples (30, 200, and 400 ng/ml). A stock solution of 2,4-
dibromoacetophenon with concentration 520 g/ml was prepared
by dissolving 52 mg in 100 ml methanol.
2.3. Preparation of Sample
To clean up the plasma samples, a simple protein precipitation
procedure was applied.8 180 l of plasma containing certain
concentrations of captopril and apigenin were added 20 l 2,4-
dibromoacetophenon working solution and ammonia 5%, vortex-
mixed for 30 Sec and stored at 25 C for 30 Min, after that added
20 l formic acid 15%, propranolol (1 g/ml) and 600 l ace-
tonitrile, vortex-mixed for 30 Sec and centrifuge at 12000 rpm
for 5 Min, after that the supernatant was transferred to an
autosampler vial and 5 l were injected into the LC-MS/MS
system.
2.4. Chromatographic Conditions
The chromatography was performed on C18 column Acquity®
(100 mm×21 mm), 1.7 m particles size column at a tempera-
ture of 40 C. The gradient system of mobile phase composition
was a mixture of 0.1% formic acid and acetonitrile (60; 40 v/v),
with flow rate 0.3 ml/second. Mass detection was used Waters
Xevo Triple Quadrupole equipped with an electrospray ioniza-
tion (ESI) source in positive ion mode in the multiple reaction
monitoring (MRM) modes.
2.5. Validation Method
The validation of LC-MS/MS method by examining its precision,
accuracy, sensitivity, selectivity, matrix effect and stability pro-
files of captopril in presence of apigenin accordingly with EMEA
2011.
Animals used in this study were approved by the Health
Research Ethics Committee of the Faculty of Medicine, Univer-
sity of Indonesia. The reference number for notice of approval
was 666/UN2.F1/ETHICS/2016.
3. RESULTS AND DISCUSSION
3.1. Optimization of LC-MS/MS Parameters
To quantify captopril in presence of apigenin in rat plasma
sample, needed a selective and sensitive methodology for accu-
rate pharmacokinetic examination especially at low plasma level.
Captopril is very unstable, undergoes to oxidation, the degra-
dation product being the dimer and also binds to endogenous
compounds (cysteine, glutathione). To improve stabilize the com-
pound a derivatizing agent 2,4-dibromoacetophenon can be used,
which prevents captopril binding to plasma constituents and is
also a chemical stabilizer.7
Mass detection was used Water Xevo TQD equipped with
electrospray ionization (ESI) source in positive ion mode in the
multiple reaction monitoring (MRM) modes. The following oper-
ational parameter of the ions cone and collision energies are pre-
sented in Table I. Captopril was detected at m/z 415 > 21616,
apigenin was detected at m/z 27113 > 15307 and propranolol
as an internal standard was detected at m/z 260> 18317.
The full spectrum scan was dominated by protonated
molecules m/z 415 for captopril and 271,13 for apigenin, and the
major fragmentations observed in each product spectrum were
at m/z 216,16 and 153,07 (Figs. 1 and 2). Chromatogram of
captopril, apigenin, and propranolol simultaneously is given in
Figure 3.
3.2. Validation Assay
A validity test of LC-MS/MS method includes its selectivity, sen-
sitivity, precision, accuracy, matrix effect and stability9 profiles
of captopril in the presence of apigenin.
3.3. Calibration Curve and Lower Limit of
Quantification (LLOQ)
The calibration curves were linear over the concentration range of
10–500 ng/ml and linearity of 0.9992, the LLOQ were 10 ng/ml.
The precision value (%CV) of Within-run and between-run
analysis is 3.90–10.90% and 3.77–8.13% was less than 20%
(Table II).
3.4. Selectivity
The selectivity was evaluated by analyzing blank plasma sample
and blank plasma spiked with captopril, apigenin, and propra-
nolol (internal standard). The result showed that there was no
interference endogenous compound from the blank plasma of the
six different sources, whereas the %diff of captopril was less than
20%.
3.5. Carry Over
Carry over value after high concentration injection was 2.26%
for captopril and 1.22% propranolol from LLOQ response, with
the presence of apigenin. The value of carrying over-fulfilled
the acceptance criteria for analyte <20% and for the internal
standard <5%.
3.6. Precision and Accuracy
Precision and accuracy of captopril in presence of apigenin were
calculated by within run and between run variation of QC sample
Table I. Result of optimization detection of LC-MS/MS.
Cone Collison
Compound Parent (m/z) Daughter (m/z) voltage energy Area
Captopril 415 216,16 35 17 305×105
Propranolol 260 183,17 42 17 559×106
Apigenin 271,13 153,07 61 31 703×106
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Fig. 1. Fragmentation of ion mass spectrum of captopril.
Fig. 2. Fragmentation of ion mass spectrum of apigenin.
in five replication at four concentration as shown in Table II.
The precision (%CV) value of within run and between run
analysis is 3.90–10.90% and 3.77–8.13%, whereas the accuracy
(%diff) of captopril less than 20%. The within run and between
run precision and accuracy values indicate the adequate relia-
bility and reproducibility of the method within the analytical
range.
3.7. Matrix Effect
Ion increasing effects due to matrix constituents were
observed which the value of matrix effect on the low
Fig. 3. Chromatogram of captopril, apigenin, and propranolol. The chromatography was performed on C18 column Acquity® (100 mm×21 mm), 1.7 m
particles size column at a temperature of 40 C. The gradient system of mobile phase composition was a mixture of 0.1% formic acid and acetonitrile (60;
40 v/v), with flow rate 0.3 ml/second, run time 5 Min.
concentration 30 ng/ml was 2,31–2,35% (%CV), was less
than 15%.
3.8. Stability Test
The stability profiles of captopril in the presence of apigenin
were assessed with different temperature and storage condition
and was performed at QCL and QCH in three replicates. The
standard solution stability was evaluated after storage at 25 C for
28 days. Such investigations included short-term stability study
(6 h at 25 C), long term stability study (−40 C for 120 days),
stability after three freeze-thaw cycles (<−20 C to 25 C) and
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Table II. Accuracy and precision of captopril in presence of apigenin.
Mean measured
Konsentrasi concentration
(ng/ml) (ng/ml)±SD (n = 5) (%CV) (%diff)
Within-run LLOQ (10) 9.73±0,38 390 −6.50–3.58
QCL (30) 29.68±3,24 1090 −14.06–11.27
QCM (200) 199.81±12,20 610 −8.90–8.22
QCH (400) 399.61±29,56 740 −12.81–3.11
Between-run LLOQ (10) 10.21±0.83 813 −13.82–12.21
QCL (30) 31.38±1.68 535 −5.32–14.41
QCM (200) 212.76±8.02 377 −0.66–13.08
QCH (400) 395.46±−1.22 421 −7.94–6.07
Table III. Stability of captopril in the presence of apigenin.
Standard solution (25 C for 28 days) (n = 3) −11.74–14.65 (%diff)
Plasma samples
(n = 3)
30 ng/ml (±SD) 400 ng/ml (±SD)
After three freezes and
thaw cycle
(<−20 C to 25 C)
32.72±0.43 411.41±19.84
Short term stability
(6 h at 25 C)
30.32±0.18 403.86±12.17
Post preparative
stability (6 h at
25 C)
32.03±1.10 419.61±4.82
Long term stability
(−40 C for
120 days)
30.85±0.25 385.13±8.61
post-preparative stability study (6 h at 25 C). The results of the
stabilities study did not deviate by more than 15% compared with
freshly prepared samples (Table III).
4. CONCLUSIONS
The LC-MS/MS method has been developed for the determina-
tion of captopril in rat plasma in presence of apigenin in vitro
and showed good selectivity, linearity, accuracy, and precision,
matrix effect and stability.
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